You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Porfimer sodium - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for porfimer sodium and what is the scope of patent protection?

Porfimer sodium is the generic ingredient in one branded drug marketed by Pinnacle Biolgs and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for porfimer sodium
US Patents:0
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 6
Clinical Trials: 32
What excipients (inactive ingredients) are in porfimer sodium?porfimer sodium excipients list
DailyMed Link:porfimer sodium at DailyMed
Recent Clinical Trials for porfimer sodium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 1
Roswell Park Cancer InstitutePhase 1
Taoyuan General HospitalEarly Phase 1

See all porfimer sodium clinical trials

Pharmacology for porfimer sodium
Drug ClassPhotoactivated Radical Generator
Mechanism of ActionPhotoabsorption
Physiological EffectPhotosensitizing Activity

US Patents and Regulatory Information for porfimer sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pinnacle Biolgs PHOTOFRIN porfimer sodium INJECTABLE;INJECTION 020451-001 Dec 27, 1995 RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for porfimer sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pinnacle Biolgs PHOTOFRIN porfimer sodium INJECTABLE;INJECTION 020451-001 Dec 27, 1995 ⤷  Sign Up ⤷  Sign Up
Pinnacle Biolgs PHOTOFRIN porfimer sodium INJECTABLE;INJECTION 020451-001 Dec 27, 1995 ⤷  Sign Up ⤷  Sign Up
Pinnacle Biolgs PHOTOFRIN porfimer sodium INJECTABLE;INJECTION 020451-001 Dec 27, 1995 ⤷  Sign Up ⤷  Sign Up
Pinnacle Biolgs PHOTOFRIN porfimer sodium INJECTABLE;INJECTION 020451-001 Dec 27, 1995 ⤷  Sign Up ⤷  Sign Up
Pinnacle Biolgs PHOTOFRIN porfimer sodium INJECTABLE;INJECTION 020451-001 Dec 27, 1995 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for porfimer sodium

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Pinnacle Biologics B.V.  PhotoBarr porfimer sodium EMEA/H/C/000493
Photodynamic therapy (PDT) with PhotoBarr is indicated for: Ablation of high-grade dysplasia (HGD) in patients with Barrett's Oesophagus (BO)
Withdrawn no no no 2004-03-25
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.